Biomx Inc
PHGE0.418USD
+0.022+5.45%
시장 운영 시간 （ET）시세는 15분 지연됩니다
10.44M시가총액
손실P/E TTM
자세한 내용은 Biomx Inc 회사
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
회사 정보
종목 코드 PHGE
회사 이름Biomx Inc
상장일Dec 18, 2018
CEOMr. Jonathan Eitan Solomon
직원 수52
유형Ordinary Share
회계 연도 종료Dec 18
주소22 Einstein St.
도시NESS-ZIONA
증권 거래소NYSE American Consolidated
국가Israel
우편 번호7414003
전화972723942377
웹사이트https://www.biomx.com/
종목 코드 PHGE
상장일Dec 18, 2018
CEOMr. Jonathan Eitan Solomon
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
179.80K
+238.89%
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
68.92K
+18278.67%
Mr. Assaf Oron
Mr. Assaf Oron
Chief Business Officer
Chief Business Officer
25.80K
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Michael Dambach
Mr. Michael Dambach
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Director
Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Director
Director
--
--
Ms. Anat Primovich
Ms. Anat Primovich
Corporate Project Manager
Corporate Project Manager
--
--
Mr. Jason Marks
Mr. Jason Marks
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
179.80K
+238.89%
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
68.92K
+18278.67%
Mr. Assaf Oron
Mr. Assaf Oron
Chief Business Officer
Chief Business Officer
25.80K
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Michael Dambach
Mr. Michael Dambach
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Director
Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jun 25
마지막 업데이트: Wed, Jun 25
주주
주주 유형
주주
주주
비율
Deerfield Management Company, L.P.
9.53%
Cystic Fibrosis Foundation
9.53%
Nantahala Capital Management, LLC
9.53%
Alyeska Investment Group, L.P.
6.08%
AIGH Capital Management, LLC.
4.52%
Other
60.82%
주주
주주
비율
Deerfield Management Company, L.P.
9.53%
Cystic Fibrosis Foundation
9.53%
Nantahala Capital Management, LLC
9.53%
Alyeska Investment Group, L.P.
6.08%
AIGH Capital Management, LLC.
4.52%
Other
60.82%
주주 유형
주주
비율
Hedge Fund
31.66%
Corporation
13.62%
Private Equity
4.52%
Holding Company
4.09%
Investment Advisor
3.77%
Venture Capital
3.72%
Investment Advisor/Hedge Fund
2.37%
Research Firm
1.65%
Individual Investor
1.48%
Other
33.12%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
47
17.51M
66.88%
+4.34M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
2023Q2
39
1.94M
47.21%
+273.60K
2023Q1
38
1.06M
33.47%
-530.41K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Deerfield Management Company, L.P.
2.49M
9.53%
+1.25M
+100.00%
Mar 31, 2025
Cystic Fibrosis Foundation
2.49M
9.53%
+706.35K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
2.49M
9.53%
+762.71K
+44.07%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.59M
6.08%
+725.34K
+83.82%
Mar 31, 2025
AIGH Capital Management, LLC.
1.18M
4.52%
+533.12K
+82.04%
Mar 31, 2025
Centaurus Investments Limited
1.07M
4.09%
+1.07M
--
Apr 21, 2025
Allostery Investments LP
940.63K
3.59%
+296.80K
+46.10%
Mar 31, 2025
Ikarian Capital LLC
892.98K
3.41%
--
--
Mar 31, 2025
AMR Action Fund LP
876.89K
3.35%
+571.40K
+187.05%
Sep 30, 2024
Telmina Ltd
560.27K
2.14%
+276.30K
+97.30%
Sep 30, 2024
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
날짜
유형
비율
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
